| |
(n = 20)
|
|---|
|
Age (years)
|
68 ± 12
|
|
Sex (male/female)
|
15/5
|
|
Smoking (%)
|
12 (60)
|
|
History of CVD (%)
|
3 (15)
|
|
Diabetes mellitus (%)
|
12 (60)
|
|
Systolic blood pressure (mmHg)
|
126.9 ± 24.3
|
|
Diastolic blood pressure (mmHg)
|
74.4 ± 15.3
|
|
eGFR (mL/min/1.73 m2)
|
71.6 ± 25.1
|
|
Indoxyl sulfate (μg/mL)
|
0.56 [0.32–0.93]
|
|
Max CK (U/L)
|
1924.0 [719.5–3067.0]
|
|
Max CK-MB (U/L)
|
207.5 [74.3–300.0]
|
|
NT-pro BNP (pg/mL)
|
159.0 [33.3–1610.0]
|
|
Dose of contrast media (mL)
|
190.7 ± 52.5
|
|
LVEF (%)
|
53.1 ± 11.3
|
|
Antiplatelet agent (%)
|
1 (5)
|
|
Statin (%)
|
4 (20)
|
|
Ca-blocker (%)
|
4 (20)
|
|
RAS-I (%)
|
5 (25)
|
|
β-blocker (%)
|
0 (0)
|
- BMI body mass index, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, CK creatine kinase, NT-pro BNP N-terminal pro-B-type natriuretic peptide, LVEF left ventricular ejection fraction, Ca-blocker calcium channel blocker, RAS-I renin-angiotensin system inhibitor
